A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report.

Autor: Ciurescu IA; Department of Medical Oncology, S.C. Pelican Impex SRL, Oradea 410450, Romania., Lencioni R; Department of Radiology, Pisa University School of Medicine, I-56126 Pisa, Italy.; Department of Radiology, Miami Cancer Institute, Miami, FL 33176, USA., Stemmer SM; Rabin Medical Center, Petah Tikva 4941492, Israel.; Faculty of Medicine, Aviv University, Aviv 6997801, Israel., Farbstein M; Can-Fite BioPharma Ltd., Petah Tikva 49170, Israel., Harpaz Z; Can-Fite BioPharma Ltd., Petah Tikva 49170, Israel., Bareket-Samish A; BioInsight Ltd., Binyamina 3056814, Israel., Silverman MH; Can-Fite BioPharma Ltd., Petah Tikva 49170, Israel., Fishman P; Can-Fite BioPharma Ltd., Petah Tikva 49170, Israel.
Jazyk: angličtina
Zdroj: Experimental and therapeutic medicine [Exp Ther Med] 2024 Apr 24; Vol. 27 (6), pp. 263. Date of Electronic Publication: 2024 Apr 24 (Print Publication: 2024).
DOI: 10.3892/etm.2024.12551
Abstrakt: Established treatments for advanced hepatocellular carcinoma (HCC) with Child-Pugh cirrhosis B (CPB, moderate hepatic dysfunction) are lacking. A recently published randomized phase 2 study in CPB HCC investigating the safety and efficacy of namodenoson (25 mg BID), an A3 adenosine-receptor agonist vs. placebo, suggested a favorable safety profile and a positive efficacy signal in patients with HCC with a CPB score of 7 (CPB7). The present study reports a 61-year-old woman with CPB7 HCC who received namodenoson for over 6 years through this study and its open-label extension. Computed tomography scans demonstrated partial and complete responses after 7 weeks and 4 years of treatment, respectively. Low albumin levels (31 g/l) and elevated baseline levels of alanine transaminase and aspartate aminotransferase (68 U/l and 44 U/l, respectively) were reported. After 4 weeks of treatment, these levels normalized and were stable for over 6 years. No treatment-emergent adverse events were noted. At the time of reporting, the response is ongoing as manifested by imaging studies and liver function evaluation.
Competing Interests: MF, ZH, MHS, and PF are Can-Fite BioPharma, Ltd employees. SMS received research grant and stock options from Can-Fite BioPharma Ltd. AB-S is a consultant for Can-Fite BioPharma Ltd. The remaining authors declare no competing interests. Can-Fite BioPharma sponsored the phase 2 study; however, this sponsorship had no bearing on the results of the study or their scientific interpretation.
(Copyright: © 2024 Ciurescu et al.)
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje